Axcella surges on U.S. application for human study of long COVID fatigue treatment

Axcella Health

23/01/2023 22:22

** Shares of drug developer Axcella Health Inc  AXLA.O 
surge ~63% to 69 cents after the bell, top gainer across U.S.
exchanges
    ** Says submitted application to FDA to conduct mid-to-late
stage human trial of its long COVID fatigue treatment AXA1125
    ** Adds received regulatory guidance from U.K.'s MHRA that
aligns on key measurements for a registration trial, including
primary goal and trial design elements
    ** The submission is supported by results from a mid-stage
study evaluating the efficacy and safety of AXA1125 in patients
with fatigue related to long COVID
    ** Co lost ~84% last year 
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))